| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | AGTR1; AGTR1A; AGTR1B; AT2R1; AT2R1B; Type-1 angiotensin II receptor; AT1AR; AT1BR; Angiotensin II type-1 receptor; AT1 |
| Entrez GeneID | 185 |
| WB Predicted band size | Calculated MW: 41 kDa; Observed MW: 41 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human AGTR1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于Angiotensin II Type 1 Receptor(AT1R)抗体的代表性文献摘要：
1. **文献名称**：*Autoantibodies from preeclamptic patients induce vascular dysfunction through angiotensin receptor activation*
**作者**：Xia Y., et al.
**摘要**：该研究发现，子痫前期患者血清中的AT1R自身抗体可通过激活血管平滑肌细胞上的AT1受体，导致细胞内钙离子浓度升高和血管收缩，提示这类抗体在妊娠高血压病理机制中的直接作用。
2. **文献名称**：*Role of angiotensin II type 1 receptor antibodies in the pathogenesis of hypertension*
**作者**：Walther T., et al.
**摘要**：研究证明，AT1R抗体在动物模型中可通过结合受体胞外第二环表位，激活下游MAPK信号通路，导致血管炎症和血压升高，提示其在原发性高血压中的潜在致病性。
3. **文献名称**：*Agonistic antibodies directed at the angiotensin II type 1 receptor in patients with renal disease*
**作者**：Dechend R., et al.
**摘要**：该文献报道，慢性肾脏病患者体内存在的AT1R抗体可通过激活NADPH氧化酶途径促进活性氧(ROS)生成，导致肾小球内皮细胞损伤和纤维化进展。
4. **文献名称**：*Autoantibodies targeting G protein-coupled receptors in systemic sclerosis*
**作者**：Riemekasten G., et al.
**摘要**：研究发现，系统性硬化症患者的AT1R抗体会与受体结合并诱导胶原合成增加，提示其在器官纤维化中的病理作用，可能成为治疗靶点。
以上文献均聚焦于AT1R抗体的功能机制及其在疾病中的病理意义，涵盖妊娠高血压、肾脏病和自身免疫性疾病等领域。
The angiotensin II type 1 receptor (AT1R) is a G protein-coupled receptor that plays a central role in the renin-angiotensin system (RAS), regulating blood pressure, fluid balance, and cardiovascular homeostasis. AT1R antibodies (AT1R-Abs) are autoantibodies that target this receptor, often acting as agonists to induce sustained receptor activation. Initially identified in preeclampsia and malignant hypertension, these antibodies are now linked to a broader spectrum of pathologies, including kidney transplant rejection, autoimmune disorders, and cardiovascular diseases.
AT1R-Abs are typically detected via immunoassays (e.g., ELISA or cell-based assays) and are distinct from other RAS-targeting antibodies like those against angiotensin II itself. Their pathogenic mechanism involves binding to AT1R's extracellular domains, triggering intracellular signaling cascades (e.g., ERK1/2. NF-κB) that promote vasoconstriction, inflammation, and fibrosis. In transplantation, donor-specific AT1R-Abs correlate with antibody-mediated rejection and graft loss, even in HLA-compatible cases.
Clinically, AT1R-Ab testing is gaining traction as a biomarker for refractory hypertension or unexplained organ dysfunction. Therapeutic strategies focus on RAS blockade (e.g., ARBs, ACE inhibitors) and immunomodulation (e.g., plasmapheresis, rituximab). Research continues to explore their role in autoimmune-driven cardiovascular diseases, highlighting AT1R-Abs as both diagnostic tools and therapeutic targets in precision medicine.
×
